Tiffany Wallace is a Program Director in the Office of the Director of the NCI’s CRCHD. In this role, Dr. Wallace contributes to CRCHD’s programmatic efforts to strengthen NCI’s cancer health disparity research portfolio, encompassing basic, clinical, translational, and population-based research. Additional roles include contributing to the grant management of basic and translational research in cancer health disparities and representing CRCHD in disparities-related working groups and committees across NCI and NIH. Prior to joining NCI, Dr. Wallace was an Oncology Scientist at Human Genome Sciences (HGS), a biopharmaceutical corporation acquired by GlaxoSmithKline in 2011. While at HGS she managed oncology research programs and conducted preclinical development of promising cancer therapeutic drugs and biologics. Dr. Wallace received her PhD in biomedical sciences from the University of Florida in Gainesville. She completed her postdoctoral training in the Laboratory of Human Carcinogenesis at NCI, where she conducted basic and translational research that provided novel insights on the role of biological factors as they contribute to cancer health disparities. Her research included identification of biomarkers of aggressive disease in prostate and breast cancers, with a focus on variations between different racial/ethnic groups.